Q-Line Biotech September-half profit falls 6% as cash outflows

Q-Line Biotech Limited reported standalone profit of Rs 20.22 crore for the half year ended 30 September 2026, down 6.1% from a year earlier, while revenue from operations rose 5.9% to Rs 152.07 crore and operating activities used Rs 8.47 crore of cash after tax and working-capital movements.

Why did Q-Line Biotech’s September-half profit decline?

Q-Line Biotech’s standalone profit for the period declined to Rs 20.22 crore in the half year ended 30 September 2026 from Rs 21.53 crore in the corresponding half year ended 30 September 2025. Profit before tax, however, increased marginally to Rs 26.75 crore from Rs 26.54 crore, while total tax expense rose to Rs 6.54 crore from Rs 5.01 crore.

Revenue from operations increased to Rs 152.07 crore from Rs 143.60 crore, and total revenue including other income rose to Rs 156.14 crore from Rs 146.26 crore. Total expenses increased to Rs 129.39 crore from Rs 119.72 crore, with purchase of stock-in-trade at Rs 34.43 crore, other expenses at Rs 36.34 crore and depreciation and amortisation at Rs 7.88 crore.

Which Q-Line Biotech segment changed during the half year?

Q-Line Biotech’s trading segment provided the year-on-year revenue increase, reporting Rs 64.04 crore for the September 2026 half year against Rs 54.06 crore a year earlier. Manufacturing revenue declined to Rs 88.03 crore from Rs 89.54 crore, although it remained the larger of the company’s two reported segments.

Q-Line Biotech reports manufacturing and trading of biochemistry reagents, instruments and consumables as its segments under Accounting Standard 17. Manufacturing segment result before finance costs and tax increased to Rs 52.77 crore from Rs 42.91 crore, whereas trading segment result declined to Rs 17.41 crore from Rs 18.71 crore.

The preceding-half comparison showed lower total revenue in the September 2026 period. Revenue from operations was Rs 152.07 crore, compared with Rs 197.56 crore in the half year ended 31 March 2026, as manufacturing revenue fell from Rs 140.69 crore; trading revenue increased from Rs 56.87 crore to Rs 64.04 crore.

Why did Q-Line Biotech report negative operating cash flow?

Q-Line Biotech reported net cash outflow from operating activities of Rs 8.47 crore for the half year ended 30 September 2026. The cash-flow statement compares this with an inflow of Rs 20.97 crore for the full year ended 31 March 2026, so the disclosed comparative periods are not like for like.

Cash generated from operations before tax was Rs 4.55 crore in the September half, but tax paid was Rs 13.01 crore. Working-capital movements included a Rs 13.06 crore increase in inventory, a Rs 11.84 crore increase in trade receivables, a Rs 9.25 crore increase in short-term loans and advances, and a Rs 14.32 crore decline in trade payables.

The standalone balance sheet records these movements at 30 September 2026. Inventory stood at Rs 107.82 crore versus Rs 94.76 crore at 31 March 2026, trade receivables were Rs 138.56 crore versus Rs 126.91 crore, and short-term loans and advances were Rs 52.78 crore versus Rs 36.03 crore.

How did Q-Line Biotech deploy share proceeds and reduce borrowings?

Q-Line Biotech recorded Rs 241.92 crore of proceeds from issue of share capital during the half year ended 30 September 2026, with issue expenses of Rs 26.21 crore. It also placed Rs 107.62 crore of unutilised initial public offering proceeds in bank term deposits, recorded as an investing cash outflow.

Financing activities produced a net cash inflow of Rs 113.39 crore, while investing activities used Rs 113.19 crore. The financing cash flow included repayment of Rs 27.99 crore of short-term borrowings and Rs 64.77 crore of long-term borrowings, alongside Rs 9.56 crore of finance cost.

On the standalone balance sheet, long-term borrowings declined to Rs 21.35 crore at 30 September 2026 from Rs 86.12 crore at 31 March 2026. Short-term borrowings declined to Rs 98.85 crore from Rs 126.84 crore, while other bank balances rose to Rs 152.28 crore from Rs 35.20 crore.

What are Q-Line Biotech’s reporting basis and disclosed next steps?

Q-Line Biotech’s unaudited standalone results for the half year ended 30 September 2026 were reviewed by the audit committee and approved by the board on 12 November 2026. The statutory auditor issued an unmodified limited review report under Regulation 33 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015.

Q-Line Biotech prepared the financial statements using Accounting Standards rather than Indian Accounting Standards, citing its listing on the National Stock Exchange SME platform. The company also said it continues to monitor final central and state rules and government clarifications on the four labour codes notified on 21 November 2025, and would record an accounting effect if required.

The board also approved acquisition of 612,500 equity shares, representing 70% of Heidelco Medicore Private Limited’s paid-up share capital, on 12 November 2026. Q-Line Biotech said the related-party transaction’s valuation basis was net asset value as at 30 September 2026.

Conclusion

Q-Line Biotech’s September 2026 half-year figures show revenue growth alongside a lower standalone profit, with the higher tax charge contributing to the difference between the Rs 26.75 crore pre-tax profit and Rs 20.22 crore profit for the period. Trading added Rs 9.98 crore of revenue year on year, while inventory, receivables, advances and lower trade payables contributed to the Rs 8.47 crore operating cash outflow.

The next disclosed matters to watch are deployment of the Rs 107.62 crore of unutilised initial public offering proceeds held in term deposits, completion and financial effects of the approved 70% Heidelco Medicore Private Limited acquisition, and any accounting impact from final labour-code rules or government clarifications.